The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease

[1]  Z. Yue,et al.  Autophagy in neurodegenerative diseases , 2016, Brain Research.

[2]  F. Di Domenico,et al.  mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy , 2015, Neurobiology of Disease.

[3]  A. Richardson,et al.  How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story , 2015, Experimental Gerontology.

[4]  B. Winblad,et al.  mTor mediates tau localization and secretion: Implication for Alzheimer's disease. , 2015, Biochimica et biophysica acta.

[5]  F. Inagaki,et al.  Mechanisms of Autophagy. , 2015, Annual review of biophysics.

[6]  D. Butterfield,et al.  Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre‐clinical AD, amnestic mild cognitive impairment and late‐stage AD , 2015, Journal of neurochemistry.

[7]  Junying Yuan,et al.  Autophagy in Neurodegenerative Diseases: From Mechanism to Therapeutic Approach , 2015, Molecules and cells.

[8]  W. Wang,et al.  Inhibition of mTOR pathway restrains astrocyte proliferation, migration and production of inflammatory mediators after oxygen–glucose deprivation and reoxygenation , 2015, Neurochemistry International.

[9]  B. Davidson,et al.  Reinstating Aberrant mTORC1 Activity in Huntington’s Disease Mice Improves Disease Phenotypes , 2015, Neuron.

[10]  K. Guan,et al.  mTOR: a pharmacologic target for autophagy regulation. , 2015, The Journal of clinical investigation.

[11]  S. Harper.  Economic and social implications of aging societies , 2014, Science.

[12]  E. Aronica,et al.  mTOR Hyperactivation in down syndrome hippocampus appears early during development. , 2014, Journal of neuropathology and experimental neurology.

[13]  A. Messina,et al.  Genetic Reduction of Mammalian Target of Rapamycin Ameliorates Alzheimer's Disease-Like Cognitive and Pathological Deficits by Restoring Hippocampal Gene Expression Signature , 2014, The Journal of Neuroscience.

[14]  P. Codogno,et al.  Regulation of autophagy by amino acids and MTOR-dependent signal transduction , 2014, Amino Acids.

[15]  N. Inestrosa,et al.  Signaling pathway cross talk in Alzheimer’s disease , 2014, Cell Communication and Signaling.

[16]  L. Tan,et al.  Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in cellular and animal models of Alzheimer's disease. , 2014, Pharmacological research.

[17]  M. Costa-Mattioli,et al.  mTOR complexes in neurodevelopmental and neuropsychiatric disorders , 2013, Nature Neuroscience.

[18]  W. Sossin,et al.  A recollection of mTOR signaling in learning and memory. , 2013, Learning & memory.

[19]  O. Gavrilova,et al.  Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. , 2013, Cell reports.

[20]  L. Tan,et al.  Targeting the mTOR Signaling Network for Alzheimer’s Disease Therapy , 2013, Molecular Neurobiology.

[21]  M. Blagosklonny,et al.  Rapamycin suppresses brain aging in senescence-accelerated OXYS rats , 2013, Aging.

[22]  Min Jae Lee,et al.  Tau degradation: The ubiquitin–proteasome system versus the autophagy-lysosome system , 2013, Progress in Neurobiology.

[23]  Alcino J. Silva,et al.  mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies , 2013, Aging cell.

[24]  Rui M. M. Branca,et al.  Mammalian Target of Rapamycin (mTor) Mediates Tau Protein Dyshomeostasis , 2013, The Journal of Biological Chemistry.

[25]  Lan Ye,et al.  Rapalogs and mTOR inhibitors as anti-aging therapeutics. , 2013, The Journal of clinical investigation.

[26]  K. Krnjević,et al.  mTORC2 controls actin polymerization required for consolidation of long-term memory , 2013, Nature Neuroscience.

[27]  P. Rabinovitch,et al.  mTOR is a key modulator of ageing and age-related disease , 2013, Nature.

[28]  S. Austad,et al.  Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice , 2012, Neuroscience.

[29]  E. Mandelkow,et al.  Degradation of tau protein by autophagy and proteasomal pathways. , 2012, Biochemical Society transactions.

[30]  Bin Zhao,et al.  Mammalian target of rapamycin: A valid therapeutic target through the autophagy pathway for alzheimer's disease? , 2012, Journal of neuroscience research.

[31]  A. Caccamo,et al.  Lifelong rapamycin administration ameliorates age‐dependent cognitive deficits by reducing IL‐1β and enhancing NMDA signaling , 2012, Aging cell.

[32]  M. L. Montesinos,et al.  Deregulated mTOR-mediated translation in intellectual disability , 2012, Progress in Neurobiology.

[33]  Smita Majumder,et al.  Inducing Autophagy by Rapamycin Before, but Not After, the Formation of Plaques and Tangles Ameliorates Cognitive Deficits , 2011, Alzheimer's & Dementia.

[34]  D. Rubinsztein,et al.  Autophagy and Aging , 2011, Cell.

[35]  Marta Martínez-Vicente,et al.  Fighting neurodegeneration with rapamycin: mechanistic insights , 2011, Nature Reviews Neuroscience.

[36]  Ralph A. Nixon,et al.  Autophagy failure in Alzheimer's disease—locating the primary defect , 2011, Neurobiology of Disease.

[37]  M. Giustetto,et al.  Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. , 2011, Human molecular genetics.

[38]  A. Caccamo,et al.  Naturally Secreted Amyloid-β Increases Mammalian Target of Rapamycin (mTOR) Activity via a PRAS40-mediated Mechanism* , 2011, The Journal of Biological Chemistry.

[39]  D. Rubinsztein,et al.  Regulation of mammalian autophagy in physiology and pathophysiology. , 2010, Physiological reviews.

[40]  E. Klann,et al.  Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[41]  D. Klionsky.  The autophagy connection. , 2010, Developmental cell.

[42]  Arlan Richardson,et al.  Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. , 2010, The Journal of biological chemistry.

[43]  Chang Hwa Jung,et al.  mTOR regulation of autophagy , 2010, FEBS letters.

[44]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[45]  M. Blagosklonny.  Calorie restriction: Decelerating mTOR-driven aging from cells to organisms (including humans) , 2010, Cell cycle.

[46]  D. Klionsky,et al.  Regulation mechanisms and signaling pathways of autophagy. , 2009, Annual review of genetics.

[47]  Janet M. Thornton,et al.  Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span , 2009, Science.

[48]  Alcino J. Silva,et al.  From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. , 2009, Journal of intellectual disability research : JIDR.

[49]  Tsuyoshi Morita,et al.  Specification of Neuronal Polarity Regulated by Local Translation of CRMP2 and Tau via the mTOR-p70S6K Pathway* , 2009, The Journal of Biological Chemistry.

[50]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[51]  C. Proud,et al.  mTOR's role in ageing: protein synthesis or autophagy? , 2009, Aging.

[52]  N. Mizushima,et al.  [Autophagy in embryogenesis and cell differentiation]. , 2008, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[53]  A. Cuervo,et al.  Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function , 2008, Nature Medicine.

[54]  Alcino J. Silva,et al.  Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis , 2008, Nature Medicine.

[55]  Ralph A. Nixon,et al.  Autophagy Induction and Autophagosome Clearance in Neurons: Relationship to Autophagic Pathology in Alzheimer's Disease , 2008, The Journal of Neuroscience.

[56]  H. Tanila,et al.  Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Aβ overproduction , 2008, FEBS letters.

[57]  D. Dias-Santagata,et al.  Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. , 2007, Molecular biology of the cell.

[58]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[59]  J. Holloszy,et al.  Caloric restriction in humans , 2007, Experimental Gerontology.

[60]  C. Proud,et al.  The mTOR pathway in the control of protein synthesis. , 2006, Physiology.

[61]  Jacob D. Jaffe,et al.  mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s , 2006, Current Biology.

[62]  O. Meyuhas,et al.  Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. , 2006, Trends in biochemical sciences.

[63]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[64]  J. Shulman,et al.  TOR-Mediated Cell-Cycle Activation Causes Neurodegeneration in a Drosophila Tauopathy Model , 2006, Current Biology.

[65]  B. Winblad,et al.  P70 S6 kinase mediates tau phosphorylation and synthesis , 2006, FEBS letters.

[66]  L. Tjernberg,et al.  Macroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease , 2005, The Journal of cell biology.

[67]  M. Paccalin,et al.  mTOR/p70S6k signalling alteration by Aβ exposure as well as in APP‐PS1 transgenic models and in patients with Alzheimer's disease , 2005, Journal of neurochemistry.

[68]  R. Ravid,et al.  Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology , 2005, Journal of neurochemistry.

[69]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[70]  Di Chen,et al.  The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span , 2004, Development.

[71]  M. Murakami,et al.  mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells , 2004, Molecular and Cellular Biology.

[72]  S. Benzer,et al.  Regulation of Lifespan in Drosophila by Modulation of Genes in the TOR Signaling Pathway , 2004, Current Biology.

[73]  M. Tohyama,et al.  An RNA‐dependent protein kinase is involved in tunicamycin‐induced apoptosis and Alzheimer's disease , 2004, The EMBO journal.

[74]  Tibor Vellai,et al.  Genetics: Influence of TOR kinase on lifespan in C. elegans , 2003, Nature.

[75]  P. Sanna,et al.  Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[76]  H. Braak,et al.  Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. , 2003, The American journal of pathology.

[77]  R. Chang,et al.  Phosphorylation of eukaryotic initiation factor-2&agr; (eIF2&agr;) is associated with neuronal degeneration in Alzheimer's disease , 2002, Neuroreport.

[78]  A. Gingras,et al.  A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[79]  V. Longo,et al.  Regulation of Longevity and Stress Resistance by Sch9 in Yeast , 2001, Science.

[80]  E. Hafen,et al.  Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. , 2000, Genes & development.

[81]  E. Hafen,et al.  Drosophila S6 kinase: a regulator of cell size. , 1999, Science.

[82]  S. Gygi,et al.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.

[83]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[84]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[85]  S. Squazzo,et al.  Evidence that production and release of amyloid beta-protein involves the endocytic pathway. , 1994, The Journal of biological chemistry.

[86]  J. Walker,et al.  Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[87]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[88]  D. Selkoe,et al.  Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[89]  L. Buée,et al.  Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice. , 2015, Journal of Alzheimer's disease : JAD.

[90]  N. Martínez‐López,et al.  Autophagy and aging. , 2015, Advances in experimental medicine and biology.

[91]  J. Götz,et al.  How it all started: tau and protein phosphatase 2A. , 2013, Journal of Alzheimer's disease : JAD.

[92]  S. Oddo.  The role of mTOR signaling in Alzheimer disease. , 2012, Frontiers in bioscience.

[93]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[94]  B. Winblad,et al.  p70 S6 kinase and tau in Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[95]  Y. Ihara,et al.  Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. , 1986, Journal of biochemistry.